Clinical Trial to Assess the Efficacy and Safety of Tacrolimus Ointment Treatment of Atopic Dermatitis in Adult Patients
NCT ID: NCT00523952
Last Updated: 2014-09-01
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE3
303 participants
INTERVENTIONAL
2004-01-31
2005-09-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Treatment and Control of Atopic Dermatitis With 0.1% Tacrolimus Ointment
NCT00480610
Treatment and Control of Atopic Dermatitis With 0.03% Tacrolimus Ointment
NCT00480896
Distribution of Tacrolimus in Skin, Atopic Dermatitis
NCT00534508
Study to Evaluate the Efficacy and Safety of 0.1% and 0.03% Tacrolimus Ointment Administered in Adults With Moderate to Severe Atopic Dermatitis
NCT00691145
Study to Evaluate the Response to Treatment and Safety of 0.03% Tacrolimus (FK506) Ointment Administered in Pediatric Patients With Moderate to Severe Atopic Dermatitis
NCT00691262
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SINGLE_GROUP
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
1
tacrolimus ointment
tacrolimus, single arm, 0.1 ointment
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
tacrolimus ointment
tacrolimus, single arm, 0.1 ointment
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Moderate to severe atopic dermatitis
* Has given informed consent
Exclusion Criteria
* Pregnant or breast-feeding
* Skin infection on the affected area
16 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Astellas Pharma Inc
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Central Contact
Role: STUDY_DIRECTOR
Astellas Pharma GmbH
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Brno, , Czechia
Hradec Králové, , Czechia
Ostrava, , Czechia
Pilsen, , Czechia
Prague, , Czechia
Tábor, , Czechia
Ústí nad Labem, , Czechia
Budapest, , Hungary
Debrecen, , Hungary
Győr, , Hungary
Kecskemét, , Hungary
Miskolc, , Hungary
Pécs, , Hungary
Bialystok, , Poland
Częstochowa, , Poland
Gdansk, , Poland
Katowice, , Poland
Krakow, , Poland
Lodz, , Poland
Lublin, , Poland
Poznan, , Poland
Sopot, , Poland
Szczecin, , Poland
Warsaw, , Poland
Wroclaw, , Poland
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
FG-506-06-CEE-01
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.